ReviewHeart failure reviews2020
Endomyocardial fibrosis: past, present, and future.
Review in Heart failure reviews, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 51 citations in OpenAlex.
- A Narrative Review on Endomyocardial Fibrosis: Unraveling an Under-Recognized Tropical Heart Disease.Cureus · 2025Review
- Endomyocardial fibrosis: recent advances and future therapeutic targets.Nature reviews. Cardiology · 2025Review
- Multimodality imaging analysis of the spectrum of endomyocardial fibrosis involvement in a clinical case series.European heart journal. Case reports · 2025Article
- Rheumatic Heart Disease and Endomyocardial Fibrosis: A Complex Novel Case of Heart Failure.JACC. Case reports · 2024Article
- Intramyocardial calcification in apical hypertrophic cardiomyopathy assessed using multimodality imaging: a case series.ESC heart failure · 2024Article
- [Endomyocardial fibrosis: case report].Archivos de cardiologia de Mexico · 2024Article
- Myocardial Late Gadolinium Enhancement (LGE) in Cardiac Magnetic Resonance Imaging (CMR)-An Important Risk Marker for Cardiac Disease.Journal of cardiovascular development and disease · 2024Review
- Recent Progresses in the Multimodality Imaging Assessment of Myocardial Fibrosis.Reviews in cardiovascular medicine · 2024Review
- p53 and Myofibroblast Apoptosis in Organ Fibrosis.International journal of molecular sciences · 2023Review
- Elucidating the role of circNFIB in myocardial fibrosis alleviation by endogenous sulfur dioxide.BMC cardiovascular disorders · 2022Article
- [Cardiac MRI in nonischemic cardiomyopathies].Radiologie (Heidelberg, Germany) · 2022Review
- Overview of Restrictive Cardiomyopathies.Methodist DeBakey cardiovascular journal · 2022Review
- Endomyocardial Fibrosis as a Rare Cause of Heart Transplantation and its Association with Thrombophilia: A Case Report.Arquivos brasileiros de cardiologia · 2022Article
- Fibroblast involvement in cardiac remodeling and repair under ischemic conditions.Experimental and therapeutic medicine · 2021Article
- Cardiac Fibroblasts and Cardiac Fibrosis: Precise Role of Exosomes.Frontiers in cell and developmental biology · 2019Review
- Testosterone, cardiomyopathies, and heart failure: a narrative review.Asian journal of andrologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endomyocardial fibrosis (EMF) is a neglected idiopathic disorder, predominant in tropical and subtropical regions of the developing world. It is characterized by fibrotic thickening of the endocardium and myocardium of one or both ventricles. EMF was an important cause of heart failure which accounted for up to 20% of the cases in endemic areas of Africa (rural community in Mozambique), but during the last few years, incidents of the disease have decreased considerably. Although its pathogenesis and etiology are not fully understood, its pathology resembles conditions such as eosinophilic cardiomyopathy and hypereosinophilic syndrome. Extensive fibrosis of the ventricular endocardium causing architectural distortion, impaired filling, and valvular insufficiency defines the disease. Confined to peculiar and limited geographical areas, the etiology remains blurred and it carries a grim prognosis. Medical care currently remains very challenging as one-third to half of patients with an advanced disease die within 2 years. Surgery in the correct setting can increase survival and especially in patients with advanced heart failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.